BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012;41:227-30. [PMID: 22400913 DOI: 10.3109/03009742.2011.633553] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Cui X, Dai X, Ma L, Yang C, Tan W, Zhang L, Zhang Z, Feng X, Wu R, Zou Y, Zhou Z, Lu Y, Wang Y, Wu M, Li S, Wang L, Lin H, Dong Z, Fu W, Sun X, Wang C, Ding J, Lv P, Lin J, Jiang L. Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Seminars in Arthritis and Rheumatism 2020;50:59-65. [DOI: 10.1016/j.semarthrit.2019.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
2 Dai XM, Yin MM, Liu Y, Ma LL, Ying J, Jiang LD. Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review. Chin Med J (Engl) 2020;133:975-81. [PMID: 32187045 DOI: 10.1097/CM9.0000000000000704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pacheco RL, Latorraca COC, de Souza AWS, Pachito DV, Riera R. Clinical interventions for Takayasu arteritis: A systematic review. Int J Clin Pract 2017;71. [PMID: 28895653 DOI: 10.1111/ijcp.12993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol 2021. [PMID: 33932173 DOI: 10.1007/s10067-021-05743-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Broussalis E, Trinka E, Kraus J, Mccoy M, Killer M. Treatment strategies for vasculitis that affects the nervous system. Drug Discovery Today 2013;18:818-35. [DOI: 10.1016/j.drudis.2013.05.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart 2018;104:558-65. [DOI: 10.1136/heartjnl-2016-310848] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
7 Kermani TA, Dasgupta B. Current and emerging therapies in large-vessel vasculitis. Rheumatology (Oxford) 2018;57:1513-24. [PMID: 29069518 DOI: 10.1093/rheumatology/kex385] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
8 Hočevar A, Ješe R, Rotar Ž, Tomšič M. Does leflunomide have a role in giant cell arteritis? An open-label study. Clin Rheumatol 2019;38:291-6. [DOI: 10.1007/s10067-018-4232-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
9 Sun Y, Ma L, Chen H, Kong X, Lv P, Dai X, Ji Z, Yang C, Dai S, Wu L, Zou Y, Lin J, Shi H, Yu Q, Jiang L. Analysis of predictive factors for treatment resistance and disease relapse in Takayasu’s arteritis. Clin Rheumatol 2018;37:2789-95. [DOI: 10.1007/s10067-018-4094-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dai X, Cui X, Sun Y, Ma L, Jiang L. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. Ther Adv Chronic Dis 2020;11:2040622320922019. [PMID: 32551033 DOI: 10.1177/2040622320922019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Alibaz-Oner F, Aydin SZ, Direskeneli H. Advances in the diagnosis, assessment and outcome of Takayasu’s arteritis. Clin Rheumatol. 2013;32:541-546. [PMID: 23271611 DOI: 10.1007/s10067-012-2149-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
12 Serra R, Butrico L, Fugetto F, Chibireva MD, Malva A, De Caridi G, Massara M, Barbetta A, Cannistrà M, de Franciscis S. Updates in Pathophysiology, Diagnosis and Management of Takayasu Arteritis. Ann Vasc Surg 2016;35:210-25. [PMID: 27238990 DOI: 10.1016/j.avsg.2016.02.011] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 10.4] [Reference Citation Analysis]
13 Chatterjee S, Flamm SD, Tan CD, Rodriguez ER. Clinical Diagnosis and Management of Large Vessel Vasculitis: Takayasu Arteritis. Curr Cardiol Rep 2014;16. [DOI: 10.1007/s11886-014-0499-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
14 Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Current Opinion in Rheumatology 2013;25:3-9. [DOI: 10.1097/bor.0b013e32835b133a] [Cited by in Crossref: 72] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
15 Tombetti E, Mason JC. Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology 2019;58:206-19. [DOI: 10.1093/rheumatology/key040] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
16 Alibaz-oner F, Direskeneli H. Update on Takayasu's arteritis. La Presse Médicale 2015;44:e259-65. [DOI: 10.1016/j.lpm.2015.01.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
17 Campochiaro C, Tomelleri A, Sartorelli S, Cavalli G, De Luca G, Baldissera E, Dagna L. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum 2020;50:509-14. [PMID: 32088012 DOI: 10.1016/j.semarthrit.2020.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
18 Russo RAG, Katsicas MM. Takayasu Arteritis. Front Pediatr 2018;6:265. [PMID: 30338248 DOI: 10.3389/fped.2018.00265] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 9.7] [Reference Citation Analysis]
19 Esatoglu SN, Hatemi G. Takayasu arteritis. Curr Opin Rheumatol 2022;34:18-24. [PMID: 34698679 DOI: 10.1097/BOR.0000000000000852] [Reference Citation Analysis]
20 Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology 2014;53:793-801. [DOI: 10.1093/rheumatology/ket320] [Cited by in Crossref: 108] [Cited by in F6Publishing: 86] [Article Influence: 13.5] [Reference Citation Analysis]
21 Misra DP, Wakhlu A, Agarwal V, Danda D. Recent advances in the management of Takayasu arteritis. Int J Rheum Dis 2019;22:60-8. [DOI: 10.1111/1756-185x.13285] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
22 Ying S, Xiaomeng C, Xiaomin D, Jiang L, Peng L, Lili M, Rongyi C, Zongfei J, Huiyong C, Lindi J. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis 2020;12:1759720X20930114. [PMID: 32536986 DOI: 10.1177/1759720X20930114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Keser G, Aksu K. What is new in management of Takayasu arteritis? Presse Med 2017;46:e229-35. [PMID: 28774475 DOI: 10.1016/j.lpm.2016.11.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
24 Barra L, Yang G, Pagnoux C. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. Autoimmunity Reviews 2018;17:683-93. [DOI: 10.1016/j.autrev.2018.01.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
25 Ryan C, Barbour A, Burke L, Sheppard MN. Non-infectious aortitis of the ascending aorta: a histological and clinical correlation of 71 cases including overlap with medial degeneration and atheroma—a challenge for the pathologist. J Clin Pathol 2015;68:898-904. [DOI: 10.1136/jclinpath-2015-203061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
26 Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Nölle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zänker M, Hellmich B. [S2k guidelines: management of large-vessel vasculitis]. Z Rheumatol 2020;79:67-95. [PMID: 33156399 DOI: 10.1007/s00393-020-00893-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
27 Christiansen ME, O'Carroll CB, Kumar G, Larsen BT, Dumitrascu OM. Transcranial Doppler Evaluation in Takayasu Arteritis With Oculo-Cerebrovascular Complications. Neurologist 2019;24:17-21. [PMID: 30586029 DOI: 10.1097/NRL.0000000000000202] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wu C, Sun Y, Cui X, Wu S, Ma L, Chen H, Yan Y, Ji Z, Liu Y, Lin J, Lv P, Chen R, Yang P, Jiang L. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis 2020;11:2040622320975233. [PMID: 33294149 DOI: 10.1177/2040622320975233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wang Y, Zhao Z, Gao D, Wang H, Liao S, Dong C, Luo G, Ji X, Li Y, Wang X, Zhao Y, Li K, Zhang J, Jin J, Zhang Y, Zhu J, Zhang J, Huang F. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial. Seminars in Arthritis and Rheumatism 2020;50:1513-20. [DOI: 10.1016/j.semarthrit.2020.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
30 de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, Oliveira PB, Pinheiro FA, Oliveira AC, Sato EI. Leflunomide in Takayasu arteritis - A long term observational study. Rev Bras Reumatol Engl Ed 2016;56:371-5. [PMID: 27476631 DOI: 10.1016/j.rbre.2016.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
31 Younger DS. Treatment of Vasculitis of the Nervous System. Neurol Clin 2019;37:399-423. [PMID: 30952416 DOI: 10.1016/j.ncl.2019.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Adams TN, Zhang D, Batra K, Fitzgerald JE. Pulmonary manifestations of large, medium, and variable vessel vasculitis. Respir Med 2018;145:182-91. [PMID: 30509707 DOI: 10.1016/j.rmed.2018.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
33 Misra DP, Sharma A, Kadhiravan T, Negi VS. A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmunity Reviews 2017;16:179-91. [DOI: 10.1016/j.autrev.2016.12.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
34 de Souza AWS, de Almeida Agustinelli R, de Cinque Almeida H, Oliveira PB, Pinheiro FAG, Oliveira ACD, Sato EI. Leflunomida na arterite de Takayasu – Estudo observacional de longo prazo. Revista Brasileira de Reumatologia 2016;56:371-5. [DOI: 10.1016/j.rbr.2015.09.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
35 Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638. [PMID: 24106691 DOI: 10.1155/2013/120638] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
36 Novikov PI, Smitienko IO, Moiseev SV. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 2013;32:1827-32. [DOI: 10.1007/s10067-013-2380-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
37 Muratore F, Pipitone N, Salvarani C. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Rev Clin Immunol 2017;13:345-60. [PMID: 28116918 DOI: 10.1080/1744666X.2017.1285699] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 4.5] [Reference Citation Analysis]
38 Tombetti E, Manfredi A, Sabbadini MG, Baldissera E. Management options for Takayasu arteritis. Expert Opinion on Orphan Drugs 2013;1:685-93. [DOI: 10.1517/21678707.2013.827570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
39 Sun Y, Ma L, Ma L, Kong X, Chen H, Lv P, Lin J, Liu H, Yan Y, Ji Z, Yang C, Dai S, Wan W, Zou Y, Jin X, Jiang L. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis. Rheumatol Int 2017;37:2019-26. [DOI: 10.1007/s00296-017-3847-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]